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ABSTRACT 
Use of clozapine is attended with the serious though rare risk of agranulocytosis. Clozapine-
induced agranulocytosis is reversible with the use of cytokines like granulocyte-colony stimulating 
factor (G-CSF). Reports of the haematological complication of clozapine have not been forthcom-
ing from India though it has been in use for nearly three years. This report is on an young patient 
who developed total absence of granulocytes during the 4th month of treatment who was success-
fully treated with G-CSF. 
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Clozapine is used in the treatment of 
schizophrenic patients refractory or intolerant 
to conventional neuroleptics. Its use is limited 
due to the potential risk of producing agranulo-
cytosis. The cumulative incidence of agranulo-
cytosis is 0.80% after 1 year and 0.91% after 
I1/2 years, maximum during the first 3 months 
of treatment, in women and the elderly (Alvir & 
Lieberman, 1994). The agranulocytosis due to 
clozapine is reversible but can be fatal in 0.03% 
of patients who develop the complication (Atkin 
et al., 1996). Cytokines, namely granulocyte-
macrophage colony stimulating factor (GM-
CSF) and granulocyte colony stimulating fac-
tor (G-CSF) have been used to shorten the 
course of agranulocytosis and should be con-
sidered in patients with profound neutropenia 
(Chin Yee et al., 1996). Clozapine had been in-
troduced in India for nearly three years and is 
understood to be extensively used. However no 
clinical reports of agranulocytosis have been 
reported in psychiatric literature whereas it has 
often been reported from the west where the 
monitoring protocol is as strictly followed, if not 
more. 
This paper reports an young boy who 
developed total agranulocytosis with clozapine 
and was successfully treated with G-CSF. 
CASE REPORT 
Mr. P, a 13 year old boy hailing from a 
village about 100 kms from Chennai was diag-
nosed as suffering from schizophrenia in Octo-
ber 1996 with symptoms of aggressive behav-
iour, refusal to go to school, talking incoher-
ently with a lisp, poor self care, poor concen-
tration, insomnia, hallucinatory behaviour and 
wandering tendency for the 2 months preced-
ing consultation with a psychiatrist. Neurologi-
cal evaluation including a CAT scan and EEG 
did not reveal any coarse brain disease. At the 
time of consultation with the author (TNS) he 
was receiving treatment with haloperidol and 
chlorpromazine. The boy was then seen to be 
drowsy and having parkinsonian symptoms. 
Excepting for insomnia and aggressive behav-
iour there had not been much change in his 
psychiatric picture. He was started on trifluop-
erazine and low dose benzodiazepines which 
helped reduce the drowsiness and parkinsonian 
symptoms but no further change in the overall 
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behaviour. Clozapine was then started in doses 
of 50 mg/day and increased to 125 mg/day in a 
| month. At the end of 12 weeks, the patient had 
remitted from all the symptoms of the illness 
and was showing keen interest in studies and 
was allowed to rejoin school at his village. The 
need for close monitoring of the blood counts 
was impressed upon the parents who were also 
told that if the boy developed any fever or gen-
eral ill health they should immediately report to 
the consultant, as the drug might need to be 
stopped. 
Three weeks later the boy was admitted 
to the hospital with fever and sore throat which 
had started 10 days earlier. They had consulted 
the physician near home who advised some oral 
antibiotics and advised them to continue 
clozapine. When the boy became moribund 
they brought him to the consultant. At admis-
sion the patient was febrile and dehydrated. He 
had diarrhoea and oral thrush. Skiagram of the 
: chest revealed patchy pneumonia. Blood 
hemogram revealed a total leukocyte count 
(TLC) of 1000/cmm with no neutrophils (Abso-
lute neutrophil count (ANC=0). Blood culture 
grew pseudomonas organisms. Bone marrow 
TABLE 1 
TOTAL LEUCOCYTE AND ABSOLUTE 
NEUTROPHIL COUNTS 
Time of examination 
Before clozapine 
4 weeks of clozapine 
12 weeks of clozapine 
At admission to hospital 
G-CSF given - day 1 
Day 3 
Day 5 
Day 8 
Day 10 
Day 24 
Day 60 
Leucocyte 
count /cmm 
5900 
5900 
5400 
1000 
1200 
2210 
3200 
8800 
30100 
15900 
11,100 
Neutrophil 
count /omm 
2537 
2301 
2430 
Nil 
Nil 
Nil 
288 
1908 
18361 
11178 
7500 
examination showed severe depletion of my-
eloid precursors (Promyelocyte =0 5%, 
Myeloblast =2.5%) 
The boy was kept in reverse isolation and 
started on systemic broad-spectrum antibiotics 
and antifungal agents. Granulocyte-Colony 
Stimulating Factor (G-CSF) was started on the 
2nd day after admission and given subcutane-
ously for five days at a dose of 150 micrograms 
per day. Granulocytes started appearing in the 
peripheral blood on the 5th day after starting 
G-CSF. The counts normalised in the next 3 
days and overshot the normal in 7 days. The 
cell counts done serially is given in table 1. The 
systemic infections cleared within 5 days after 
the granulocytes returned and the boy was dis-
charged after 10 days. At discharge he was 
started on risperidone. After 2 months follow-
up the boy was in remission from active symp-
toms and was attending the school though he 
tended to exhibit some negative symptoms. His 
leucoctye and neutrophil counts were normal. 
DISCUSSION 
The literature on clozapine-induced 
agraulocytosis (Gerson, 1994) had not reported 
the extreme degree of the condition as in this 
patient who had total absence of granulocytes 
in the peripheral blood corroborated by severe 
depletion of granulocyte precursor cells in the 
bone marrow. This total agranulocytosis prob-
ably occurred due to the delay between the time 
the boy developed neutropenia manifesting as 
fever and sore throat and the time of hospitali-
sation, during which time he was unfortunately 
continued on the drug. Reports of such a com-
plication in children and adolescents had not 
featured in the literature available to the au-
thors. Clozapine was used for the boy not only 
because he was intolerant and non-responsive 
to other drugs but also taking into reckoning its 
beneficial effect on the cognitive function as 
well as low risk tor tardive dyskinesia (TD) and 
other extrapyramidal symptoms (Meltzer, 1992). 
It had been observed that patients of 
schizophrenia with early onset respond 
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partially to conventional antipsychotic treatment 
and are at higher risk for developing TD (Gordon 
et al., 1994; Mozes et al . 1994) 
The importance of close monitoring of the 
granulocyte count is highlighted by the report. 
It could be argued that the boy should not have 
returned to the home town where the monitor-
ing was not followed properly. After being given 
clozapine the boy had shown significant im-
provement enabling him to rejoin school. Un-
der such circumstances denying the boy that 
opportunity by making him stay in the city is 
defeating the very purpose of using the drug. If 
only the parents followed the instruction more 
strictly and their local physician was aware of 
the complication of clozapine and acted accord-
ingly the severe complication could have been 
minimised If use of clozapine is restricted to 
only the urban patients within easy reach of 
experts, then the schizophrenic patients, ma-
jority of who live in other areas, will be denied 
the benefits due to the drug, which is obviously 
not a good policy 
All medical practitioners should be aware 
of serious adverse effects like agranulocytosis 
due to drugs and should be able to atleast moni-
tor patients who were put on the drug by the 
specialist. The concerned specialist and the 
pharmaceuticals have a responsibility in bring-
ing this awareness, especially when new drugs 
are introduced. Otherwise adverse opinion will 
build up against the use of the drug as had 
happened to clozapine when it was first intro-
duced in the 70's. 
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